Last reviewed · How we verify
NCT01159730
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Effect of Multiple Doses of VB-201 on Biomarkers
Phase 2 trial testing VB-201 or Placebo in Biomarker in 320 participants. Completed in 1 October 2011.
1 October 2011
Quick facts
| Lead sponsor | Vascular Biogenics Ltd. operating as VBL Therapeutics |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Enrollment | 320 |
| Start date | 1 October 2010 |
| Primary completion | 1 October 2011 |
| Estimated completion | 1 October 2011 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- VB-201 or Placebo — full drug profile →
Conditions studied
- Biomarker — all drugs for Biomarker →
Sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics — full company profile →
Who can join
Adults 18 to 75, any sex, with Biomarker. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to assess the safety and tolerability of multiple doses of VB-201 administered for 4 weeks and its efficacy on biomarkers.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01159730
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Biomarker
Currently open trials in the same condition.
- NCT07088874 — Novel Biomarkers and Postoperative Kidney Injury in Radical Nephrectomy · recruiting
- NCT07165236 — Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor · recruiting
- NCT06483425 — A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer · active not recruiting
- NCT06276088 — Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy · recruiting
- NCT06307314 — Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis · recruiting
Other Vascular Biogenics Ltd. operating as VBL Therapeutics trials
Trials by the same sponsor.
- NCT04733833 — A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19 · Phase 2 · completed
- NCT03398655 — A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01159730 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vascular Biogenics Ltd. operating as VBL Therapeutics
- Last refreshed: 15 November 2011
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01159730.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing